Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.57 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | IL1B | P01584 | 1/20 | 0.56 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30270624 | 1.00 | CRBN (0.57) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL25010665 | 0.89 | CRBN (0.56) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL25650421 | 0.89 | CRBN (0.56) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL23565283 | 0.89 | CRBN (0.56) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL25012122 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL30270628 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL19451306 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL30270923 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL25012124 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B | |
| SCHEMBL23065995 | 0.88 | CRBN (0.55) | CRBNIKZF3BRD4TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023125907-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | VIVIDION THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021180103-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2021-09-16 | — | — | WO | disclosed |
| WO-2021036922-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | 北京泰德制药股份有限公司 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045737-A1 | SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEO-SUBSTRATE RECRUITMENT | CRBN, CLNS1A, CDR2 | CRBN 1/4885IKZF3 1726/4885BRD4 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.